Business Wire

Janssen Demonstrates Strong Commitment to Advancing Science of Inflammatory Bowel Disease with Robust Selection of Data Presentations at 14th Congress of ECCO

Jaa

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced 18 company-sponsored abstracts will be presented at the 14th Congress of the European Crohn’s and Colitis Organisation (ECCO) taking place in Copenhagen, Denmark from 6-9 March. Highlights include six company-sponsored oral or digital oral presentations, including new data from the Phase 3 UNIFI study evaluating the efficacy and safety of STELARA® (ustekinumab) maintenance therapy in patients with moderate to severe ulcerative colitis (UC), which will be presented during the Plenary Session on 9 March.

This year marks the largest showing of data from our inflammatory bowel disease portfolio of products at ECCO, a reflection of our continued leadership and unwavering commitment to addressing unmet needs for people living with IBD,” said Scott E Plevy, MD, Gastroenterology Disease Area and IL-23 Pathway Leader, Janssen Research & Development, LLC*We are excited to present new Phase 3 maintenance data for STELARA in ulcerative colitis which are the basis of our pending regulatory applications in the European Union, US and Canada.”

A listing of abstracts is provided in the table below. Notable data presentations at ECCO include the following:

New ustekinumab data in ulcerative colitis

  • Results from the Phase 3 UNIFI study evaluating the efficacy and safety of ustekinumab as maintenance therapy in patients with moderate to severe UC who were in clinical response to a single intravenous induction of ustekinumab will be presented during a plenary session. These data were included in the recent Group Type II Variation Application to the European Medicines Agency and supplemental Biologics License Application submission to the U.S. Food and Drug Administration. (Abstract OP37)
  • Additional data from the same Phase 3 UNIFI study evaluating the effects of ustekinumab induction therapy on endoscopic healing (EH), histologic healing (HH) and combined histo-endoscopic mucosal healing (HEMH), in patients with moderate to severe UC will be presented as a digital oral. UNIFI is the first Phase 3 study to measure the effects of biologic therapy on EH and HEMH endpoint in patients with UC. Mucosal healing assesses how the colon is responding both histologically and endoscopically to therapy and both have been associated with improved, long-term clinical outcomes and a major therapeutic goal in treating patients with UC. (Abstract DOP71)

New ustekinumab data in Crohn’s disease (CD)

  • Results from the Phase 3 IM-UNITI maintenance study evaluating efficacy of ustekinumab after one year of maintenance therapy (i.e. at week 56, rather than the original week 44 primary endpoint) in patients with moderate to severe CD will be shared as a poster presentation. (Abstract P343)
Abstract No.   Title   Date/Time

OP13

Molecular response to ustekinumab in moderate-to-severe ulcerative colitis by serum protein and biopsy gene expression analysis: Results from the UNIFI Phase 3 induction study Oral presentation

Friday, March 8, 2019

8:30 AM - 10:30 AM

P406

General health status in patients with moderate to severe ulcerative colitis receiving ustekinumab: results from the Phase 3 UNIFI induction and maintenance studies Poster presentation

Friday, March 8, 2019

12:30 PM - 1:30 PM

P681

Ustekinumab therapy induced clinically meaningful improvement and remission as measured by the Inflammatory Bowel Disease Questionnaire: Results from the phase 3 UNIFI induction and maintenance studies Poster presentation

Friday, March 8, 2019

12:30 PM - 1:30 PM

P312

Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate–severe ulcerative colitis: UNIFI Poster presentation

Friday, March 8, 2019

12:30 PM - 1:30 PM

P477

Clinical remission by legacy vs. FDA definitions: definition justification and results from UNIFI Study Poster presentation

Friday, March 8, 2019

12:30 PM - 1:30 PM

P317

Characterisation of patients with delayed response to ustekinumab for Crohn’s disease Poster presentation

Friday, March 8, 2019

12:30 PM - 1:30 PM

P680

Long-term efficacy of ustekinumab with and without concomitant immunosuppressants for Crohn’s disease: results from IM-UNITI long-term extension through 2 years Poster presentation

Friday, March 8, 2019

12:30 PM - 1:30 PM

P343

Efficacy of ustekinumab in Crohn’s disease at maintenance Week 56: IM-UNITI study Poster presentation

Friday, March 8, 2019

12:30 PM - 1:30 PM

P311

Pharmacokinetics and exposure–response relationships of intravenously administered ustekinumab during induction treatment in patients with ulcerative colitis: Results from the UNIFI induction study Poster presentation

Friday, March 8, 2019

12:30 PM - 1:30 PM

DOP47

Sustained remission in patients with moderate to severe ulcerative colitis: Results from the Phase 3 UNIFI maintenance study Digital oral presentation

Friday, March 8, 2019

5:20 PM - 6:20 PM

DOP71

Effects of ustekinumab induction therapy on endoscopic and histological healing in the UNIFI Phase 3 study in ulcerative colitis

Digital oral presentation

Friday, March 8, 2019

5:20 PM - 6:20 PM

DOP54

Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial Digital oral presentation

Friday, March 8, 2019

5:20 PM - 6:20 PM

OP36

A colonic gene expression signature predicts non-response to anti-inflammatory therapies in inflammatory bowel disease Oral presentation

Saturday, March 9, 2019

10:50 AM - 12:20 PM

OP37

Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFI Oral presentation

Saturday, March 9, 2019

10:50 AM - 12:20 PM

 

The common (≥ 1/100) adverse reactions reported in controlled periods of the adult psoriasis, psoriatic arthritis and CD clinical studies with ustekinumab as well as post-marketing experience were: upper respiratory tract infection, arthralgia, back pain, diarrhoea, dizziness, fatigue, headache, infection site pain, injection site erythema, myalgia, nasopharyngitis, nausea, oropharyngeal pain, pruritus and vomiting.1

About ulcerative colitis

Ulcerative colitis affects up to 2.6 million people in Europe.2 It is a chronic disease of the large intestine, also known as the colon, in which the lining of the colon becomes inflamed and develops tiny open sores, or ulcers, that produce pus and mucus. Ulcerative colitis is the result of an abnormal response by the body's immune system. Symptoms vary, but may include loose and more urgent bowel movements, persistent diarrhoea, abdominal pain, bloody stool, loss of appetite, weight loss and fatigue.3

About the UNIFI trial

UNIFI is a Phase 3 protocol, designed to evaluate the safety and efficacy of ustekinumab induction and maintenance dosing for the treatment of moderate to severe UC in adults who demonstrated an inadequate response to, or were unable to tolerate, conventional (i.e., corticosteroids, immunomodulators) or biologic (i.e., one or more TNF blockers and/or vedolizumab) therapies. Both the induction and maintenance studies are randomised, double-blind, placebo-controlled, parallel group, multicentre studies. The induction study was conducted over a duration of at least 8 weeks for each participant. Participants achieving clinical response in the induction study were eligible for the maintenance study. The maintenance study was 44 weeks in duration. The primary endpoint of the induction study was clinical remission at week 8, and the primary endpoint for the maintenance study was clinical remission at week 44 among responders to a single intravenous ustekinumab infusion. After completion of the maintenance study, a long-term extension study will follow eligible participants for an additional three years.

About Crohn’s disease

Up to 1.7 million people across Europe are living with CD.2 Crohn’s disease is a chronic inflammatory condition of the gastrointestinal tract with no known cause, but is associated with abnormalities of the immune system that could be triggered by a genetic predisposition, diet or other environmental factors. Symptoms of CD can vary but often include abdominal pain and tenderness, frequent diarrhoea, rectal bleeding, weight loss and fever. There is currently no cure for CD.4

About the IM-UNITI trial

IM-UNITI, a Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel group study, evaluated the efficacy and safety of ustekinumab maintenance therapy in adult patients with moderate-to-severe CD. Patients who had responded to a single intravenous dose of ustekinumab in the UNITI-1 or UNITI-2 induction studies were randomised equally to receive maintenance subcutaneous ustekinumab 90 mg every 8 or 12 weeks, or placebo. In patients who met loss of response criteria between weeks 8–32, a one-time dose adjustment to 90 mg every 8 weeks occurred. All patients completing week 44 were eligible to enter the long-term extension programme, continuing their current regimen up to week 252.

About STELARA ® (ustekinumab) 1

In the European Union, ustekinumab is approved for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate (MTX) or psoralen plus ultraviolet A, and is also indicated for the treatment of moderate to severe plaque psoriasis in adolescent patients aged 12 years and older who are inadequately controlled by or are intolerant to other systemic therapies or phototherapies. In addition, ustekinumab is approved alone or in combination with MTX for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying antirheumatic drug therapy has been inadequate. In November 2016, the European Commission approved ustekinumab for the treatment of adult patients with moderately to severely active CD who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-alpha antagonist or have medical contraindications to such therapies.

The Janssen Pharmaceutical Companies of Johnson & Johnson maintain exclusive worldwide marketing rights to ustekinumab. In December 2018, a Group Type II Variation Application to the European Medicines Agency (EMA) was submitted, which seeks approval of ustekinumab for the treatment of adults with moderately to severely active UC.

About the Janssen Pharmaceutical Companies of Johnson & Johnson

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Learn more at www.janssen.com/EMEA. Follow us on Twitter: @JanssenEMEA. Janssen Research & Development, LLC is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

# # #

References

1. European Medicines Agency. (2016) Ustekinumab Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000958/WC500058513.pdf. Accessed February 2019

2. Ng SC, Shi HY, Underwood FE, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017;390:2769-78.

3. Crohn’s and Colitis UK. Ulcerative colitis. Available at: https://www.crohnsandcolitis.org.uk/about-inflammatory-bowel-disease/ulcerative-colitis. Accessed February 2019.

4. Crohn’s and Colitis UK. Crohn’s disease. Available at http://www.crohnsandcolitis.org.uk/about-inflammatory-bowel-disease/crohns-disease. Accessed February 2019.

* Limited Liability Company

Contact information

Media Enquiries:
Emily Bone
Phone: +44 787-639-4360
ebone1@its.jnj.com

Investor Relations:
Christopher DelOrefice
Phone: +1 732-524-2955

Lesley Fishman
Phone: +1 732-524-392

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Quinbrook Infrastructure Partners Launches with Mercatus26.3.2019 16:00:00 EETTiedote

Mercatus, a leading alternative asset and investment management platform, today announced the initial launch of Quinbrook Infrastructure Partners with the Mercatus Investment Lifecycle Management (ILM) Platform. Quinbrook invests in a wide range of low carbon and renewable energy infrastructure assets spanning onshore wind, utility scale and distributed solar PV, battery storage, peaking capacity and ‘smart grids’. Quinbrook recently announced final close on its latest strategy securing over USD 1.6 billion from institutional investors to support ‘value add’ investments in the US, UK and Australian markets. The Mercatus Investment Lifecycle Management (ILM) Platform systematizes and centralizes asset, fund, and portfolio data to give investors accurate analytics and real-time performance, risk, and ESG insights. “Mercatus offered us the fastest time-to-value on our biggest need: streamlining how we work with our rapidly expanding stable of portfolio companies and preparing for the digi

AerSale to Build Next Aero Air / Erickson Aero Tanker for Wildfire Suppression26.3.2019 16:00:00 EETTiedote

AerSale ®, a global supplier of mid-life aircraft, engines, used serviceable material, and maintenance, repair, and overhaul (MRO) services, announced today it has signed a contract with Aero Air / Erickson Aero Tanker to build another firefighting air tanker for the company’s fleet at AerSale’s MRO facility in Goodyear, Arizona. Conversion of the 6th MD-87 aircraft, formally begins on April 1 and will mark the sixth such aircraft modification AerSale has completed at Goodyear. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190326005165/en/ AerSale to Build Next Aero Air / Erickson Aero Tanker for Wildfire Suppression (Photo: Business Wire) “The Erickson Aero Tanker is a very versatile fire bomber and we are proud to continue our work to expand their fleet and add more aerial firefighting power to the skies,” said Charlie McDonald, Senior Vice President MRO Services at AerSale. “This modified aircraft will rank among the bes

Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection26.3.2019 15:30:00 EETTiedote

Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection. Biktarvy combines the novel, unboosted integrase strand transfer inhibitor (INSTI) bictegravir, with the demonstrated safety and efficacy profile of the Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg; FTC/TAF) dual nucleoside reverse transcriptase inhibitor (NRTI) backbone, and is the smallest INSTI-based triple-therapy STR available. Biktarvy is the first HIV product that Gilead will launch and commercialize in Japan directly through its local subsidiary, Gilead Sciences K.K. In the United States, Biktarvy has a Boxed Warning in its product label regarding the risk of post-treatment acute exacerbation of hepatitis B. See below for U.S. Important Safety Information as well as the Biktar

Clearpath Brings Velodyne Lidar Technology to Robotics Community as Value-Added Partner26.3.2019 15:00:00 EETTiedote

Velodyne Lidar, Inc. today announced Clearpath Robotics has become a value-add partner to offer its groundbreaking lidar sensors for the Clearpath research robot platform. Clearpath Robotics, headquartered in Canada, offers Velodyne sensors to academic and corporate research organizations on its mobile robots for survey and inspection, oil and gas, agriculture, materials handling and other applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190326005148/en/ Clearpath’s robotic solutions utilize Velodyne’s state-of-the-art lidar technology, which boasts industry-leading resolution, range, and field of view. (Photo: Business Wire) Clearpath’s robotic solutions utilize Velodyne’s state-of-the-art lidar technology, which boasts industry-leading resolution, range, and field of view. Velodyne sensors create a 360° real-time map of the environment, allowing the robot to detect and avoid obstacles for safe autonomous naviga

Fifth Annual Fortune 500 Employment Brand Report Published by WilsonHCG26.3.2019 15:00:00 EETTiedote

WilsonHCG, a multi-award-winning global talent solutions provider, released its fifth annual Fortune 500 Employment Brand Report. The report analyzes and ranks the employment brand of each of the Fortune 500 companies based on more than 17,000 data points around six key employment branding and promotion categories. It also identifies trends and changes to employee attraction and engagement throughout the hiring process. “Globally, this is the most competitive hiring environment in history,” said John Wilson, CEO of WilsonHCG. “One key finding from the report, many of the high ranked companies are providing candidates with a hyper-personalized experience. A positive and personalized candidate experience is more important than ever before.” Each company within the Fortune 500 was evaluated on the scope of six key employment brand categories grouped into four areas of the hiring process: Awareness & Attraction, Recruitment, Candidate Experience, and Employee Experience. “Executive leaders

ABB Wins Contract to Power the First Chinese-Built Cruise Vessel26.3.2019 14:29:00 EETTiedote

ABB has been awarded a contract to supply an integrated package, including two Azipod® steerable propulsion systems, for the construction of China’s first ever home-grown cruise ship. ABB’s deep domain knowledge in cruise technology coupled with its local expertise makes it the perfect partner to support this significant milestone in the evolution of China’s shipbuilding industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190326005501/en/ The Azipod® steerable propulsion systems, also used for the construction of China’s first ever home-grown cruise ship, due for delivery in 2023. (Photo: Business Wire) The 323-meter vessel, due for delivery in 2023, can accommodate 5,000 passengers and is designed to suit the tastes of Chinese cruise travelers whose numbers are expected to rise to 8-10 million annually by 2025, according to industry body Cruise Lines International Association (CLIA). “With this project, China is making

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme